Streetbeat News

Revenues

AMRC

Ameresco (NYSE:AMRC) was analyzed by 4 analysts, showing a mix of bullish and somewhat bullish ratings with no bearish or somewhat bearish views. The average 12-month price target is now $35.75, down from $44.50, indicating a 19.66% decline. All analysts have lowered their price targets, reflecting adjustments to market conditions and Ameresco's performance. The company's financials show strong revenue growth and net margin, but a high debt-to-equity ratio suggests financial risk.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 6:01 pm

LUNG

Analyst ratings for Pulmonx (NASDAQ:LUNG) show a mix of bullish to bearish sentiments, with recent evaluations leading to an average 12-month price target of $16.33, a 6.52% increase from the previous target. The company, known for its minimally invasive treatment for severe emphysema, has shown a notable revenue growth of 24.98% as of December 31, 2023, despite challenges in ROE and ROA. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting dynamic market conditions and company performance.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 6:00 pm

SATS

EchoStar (NASDAQ:SATS) received mixed analyst ratings with a shift towards a more neutral stance in the last quarter. The average 12-month price target was adjusted to $19.2, down from $20.56, reflecting a 6.61% decrease. Analysts from firms like Morgan Stanley, JP Morgan, UBS, and TD Cowen have updated their ratings and price targets, indicating varied expectations for EchoStar's performance. The company's financials show challenges in revenue growth, profitability, and efficiency, with a revenue decline of -8.32% and below-average net margin and ROE.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 6:00 pm

SLM

SLM (NASDAQ:SLM) has been analyzed by 4 analysts, showing a shift from bullish to indifferent sentiment in the last 30 days. The 12-month price targets suggest an average increase of 25.48% to $23.0. Analysts from JP Morgan, RBC Capital, Citigroup, and Deutsche Bank have raised their price targets, reflecting optimism about SLM's financial health, which includes strong revenue growth, net margin, ROE, and ROA, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 6:00 pm

LLY

NVO

Novo Nordisk A/S (NVO) faces shortages of Ozempic starter kits in Germany due to high demand for its weight-reducing effects, with limited availability expected through 2024. Meanwhile, a Chinese company, Hangzhou Jiuyuan Gene Engineering, has developed a biosimilar, Jiyoutai, potentially challenging Ozempic's market in China. Eli Lilly And Co (LLY) also experiences tight supply of its diabetes drug Mounjaro until 2024 due to high demand.

Portfolio Pulse from Vandana Singh

April 03, 2024 | 5:37 pm

COTY

EL

ELF

NBCC

ULTA

VSMV

Ulta Beauty, Inc. (NASDAQ:ULTA) shares are falling due to executives cautioning about a deceleration in demand across categories in Q1. Despite this, the company reaffirmed its annual comparable sales growth target of 4% to 5% and expects FY 2024 revenue to be between $11.7 billion and $11.8 billion. The news also negatively impacted shares of E.L.F. Beauty, Inc. (NYSE:ELF), Coty Inc. (NYSE:COTY), and Estee Lauder Companies, Inc. (NYSE:EL). Investors can gain exposure to ULTA through Neuberger Berman ETF Trust Neuberger Berman Next Generation Connected Consumer ETF (NYSE:NBCC) and VictoryShares US Multi-Factor Minimum Volatility ETF (NASDAQ:VSMV).

Portfolio Pulse from Nabaparna Bhattacharya

April 03, 2024 | 5:32 pm

RIVN

TSLA

Tesla Inc (NASDAQ:TSLA) has launched a 0% interest loan program in China to boost sales after experiencing a decline in market share and deliveries. Despite reducing prices, Tesla's strategy faced challenges due to competitors matching price cuts and a decrease in demand in Europe. Tesla's market share in China dropped from 10.5% to 6.7% in 2023. Rivian Automotive, Inc (NASDAQ:RIVN) reported delivering 13,588 EVs in Q1 and aims for 57,000 units in 2024. TSLA shares rose by 0.87% to $168.08.

Portfolio Pulse from Anusuya Lahiri

April 03, 2024 | 5:26 pm

NVRO

Analyst ratings for Nevro (NYSE:NVRO) have remained neutral over the last quarter, with all four analysts giving indifferent ratings. The 12-month price targets have been adjusted downwards, with an average target now at $18.00, down from a previous average of $21.00. Analysts from Citigroup, Wells Fargo, Baird, and RBC Capital have all lowered their price targets for NVRO, reflecting changing market dynamics and company performance. Nevro, a medical device company specializing in the HFX spinal cord stimulation platform, has shown a positive revenue trend with a growth rate of 2.05% as of December 31, 2023, but lags behind industry peers. The company's financial performance is strong, with exceptional net margin and ROE exceeding industry averages, and a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 5:01 pm

ELF

16 analysts have recently reviewed e.l.f. Beauty (NYSE:ELF), showing a mix of bullish to bearish sentiments. The average 12-month price target is now $198.75, up 17.17% from the previous $169.62, indicating a positive outlook. e.l.f. Beauty's financial health is strong, with significant revenue growth, high net margin, and excellent ROE and ROA, outperforming industry averages. The company's debt-to-equity ratio is also below the industry average, suggesting a healthy balance between debt and equity.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 5:00 pm

KVUE

Analysts have recently provided mixed reviews on Kenvue (NYSE:KVUE), with sentiments ranging from bullish to bearish over the past three months. The average 12-month price target for KVUE is now $22.4, a decrease from the previous $24.00. Kenvue, a spin-off from Johnson & Johnson and the world's largest pure-play consumer health company, has seen a revenue decline of -2.68% as of December 31, 2023, but maintains strong financial health indicators such as net margin and ROE.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 5:00 pm